ClinConnect ClinConnect Logo
Search / Trial NCT06143956

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Launched by ELI LILLY AND COMPANY · Nov 21, 2023

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial, called LY900038, is looking to find safe and effective ways to help adults with obesity or who are overweight manage their weight long-term. It is a Phase-2 study, which means it is testing new treatments to see how well they work. The trial has a flexible structure that allows different treatments to be tested independently. If you are between the ages of 18 and 75, have a body mass index (BMI) of 27 or higher, and have maintained a stable weight for the past three months, you might be eligible to participate.

If you join the trial, you will have the chance to try one of the new weight management interventions while being closely monitored by healthcare professionals. However, there are some important factors that could prevent you from participating, such as having certain serious health conditions or previous obesity surgeries. Overall, this trial aims to gather information that could lead to better options for managing weight for people struggling with obesity.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Have a body mass index (BMI)
  • ≥30 kilogram/square meter (kg/m²), or
  • ≥27 kg/m² and \<30 kg/m², or with at least 1 weight-related comorbidity
  • Have had a stable body weight for the 3 months prior to randomization (\<5%) body weight gain and/or loss.
  • Exclusion Criteria:
  • Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening.
  • Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
  • Have poorly controlled hypertension.
  • Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
  • * Have any of the following cardiovascular conditions within 3 months prior to screening:
  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • unstable angina, or
  • hospitalization due to congestive heart failure.
  • Have a history of symptomatic gallbladder disease within the past 2 years.
  • Have a lifetime history of suicide attempts.

About Eli Lilly And Company

Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.

Locations

Rochester, New York, United States

Walnut Creek, California, United States

Amherst, New York, United States

Phoenix, Arizona, United States

New Port Richey, Florida, United States

Louisville, Kentucky, United States

Stamford, Connecticut, United States

Rolling Hills Estates, California, United States

Nashville, Tennessee, United States

Dallas, Texas, United States

Skokie, Illinois, United States

Topeka, Kansas, United States

Phoenix, Arizona, United States

West Des Moines, Iowa, United States

Saint Peters, Missouri, United States

Cincinnati, Ohio, United States

Las Vegas, Nevada, United States

Danville, Virginia, United States

Las Vegas, Nevada, United States

Monroe, North Carolina, United States

East Syracuse, New York, United States

Dallas, Texas, United States

Miami, Florida, United States

Houston, Texas, United States

Honolulu, Hawaii, United States

Huntington Park, California, United States

Greensboro, North Carolina, United States

Port Jefferson Station, New York, United States

Huntington Park, California, United States

Greenbrae, California, United States

Troy, Michigan, United States

Springfield, Missouri, United States

Greenville, South Carolina, United States

Hialeah, Florida, United States

Chicago, Illinois, United States

Fleming Island, Florida, United States

Morehead City, North Carolina, United States

Winter Park, Florida, United States

San Antonio, Texas, United States

Mesa, Arizona, United States

East Syracuse, New York, United States

Weslaco, Texas, United States

Scottsdale, Arizona, United States

Cincinnati, Ohio, United States

San Antonio, Texas, United States

Dallas, Texas, United States

Chicago, Illinois, United States

Ammon, Idaho, United States

The Villages, Florida, United States

Rochester, New York, United States

Wenatchee, Washington, United States

New Bern, North Carolina, United States

Springfield, Missouri, United States

Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina

Ciudad Autonoma De Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina

Tucson, Arizona, United States

Needham, Massachusetts, United States

Southfield, Michigan, United States

New Bedford, Massachusetts, United States

Houston, Texas, United States

Austin, Texas, United States

Orlando, Florida, United States

Winter Park, Florida, United States

Topeka, Kansas, United States

Ciudad Autónoma De Buenos Aires, , Argentina

Stamford, Connecticut, United States

Chandler, Arizona, United States

New Bern, North Carolina, United States

Chandler, Arizona, India

Ciudad Autonoma De Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina

Honolulu, Hawaii, United States

Dallas, Texas, United States

St. Peters, Missouri, United States

West Des Moines, Iowa, United States

Buenos Aires, , Argentina

Ciudad Autonoma De Buenos Aires, , Argentina

Ciudad Autonoma De Buenos Aires, , Argentina

Patients applied

KC

KG

JP

AB

5 patients applied

Trial Officials

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4550 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST

Study Director

Eli Lilly and Company

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported